P2RY12 and acute coronary syndrome: Although guidelines favor more potent next-generation P2Y12 inhibitors, such as ticagrelor and prasugrel, in acute coronary syndrome (ACS) patients [1,2], clopidogrel remains the most widely prescribed P2Y12 inhibitor, partly due to clinical and economic factors [3].